
New Gene Target Could Improve Cholesterol Without Harming the Liver
Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.
Otman covers neurosciences, cardiology and dermatology for Michigan Medicine. A television news producer turned health care communicator, Otman specializes in storytelling, media relations and social media surrounding clinical advances, new research and compelling patient stories.
Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.
New findings give reason to pay attention to metabolic dysfunction well before middle age.
New study finds medical namesakes are losing their prominence in neurology, replaced by increasing reliance on clear, descriptive labels.
Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
Basic science research explores the effects of impaired glycine metabolism in nonalcoholic fatty liver disease and how to potentially use glycine-based treatment to help people with NAFLD.
A new drug being tested for hypertrophic cardiomyopathy changed the structure of the heart in a new report from a clinical trial.